This study aimed to explore the efficacy and safety of combination therapy with PEG-IFN α-2b and tenofovir amibufenamide (TMF) for the treatment of chronic hepatitis B (CHB). The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.